AMN Healthcare's (AMN) New Tie-Up to Boost Patient Outcome
https://www.zacks.com/stock/news/2195558/amn-healthcare-s-amn-new-tie-up-to-boost-patient-outcome?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195558
Dec 08, 2023 - AMN Healthcare's (AMN) collaboration is likely to bolster its portfolio of products and simplify the language procurement process for customers.
0
Masimo's (MASI) ORi Favored by Study for PaO2 Information
https://www.zacks.com/stock/news/2196904/masimo-s-masi-ori-favored-by-study-for-pao2-information?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196904
Dec 12, 2023 - Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.
0
Charles River (CRL) Expands 3D In Vitro Services Via New Deal
https://www.zacks.com/stock/news/2197217/charles-river-crl-expands-3d-in-vitro-services-via-new-deal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197217
Dec 13, 2023 - Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.
0
Integer Holdings Corporation (ITGR) Hit a 52 Week High, Can the Run Continue?
https://www.zacks.com/stock/news/2197283/integer-holdings-corporation-itgr-hit-a-52-week-high-can-the-run-continue?cid=CS-ZC-FT-52_week_high-2197283
Dec 13, 2023 - Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
0
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
https://www.zacks.com/stock/news/2197564/here-s-why-you-should-retain-exact-sciences-exas-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2197564
Dec 13, 2023 - Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.
0
QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes
https://www.zacks.com/stock/news/2197534/qiagen-s-qgen-strategic-alliances-aid-amid-macro-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2197534
Dec 13, 2023 - QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.
0
Integra (IART) to Advance ENT Division With New Buyout Deal
https://www.zacks.com/stock/news/2198095/integra-iart-to-advance-ent-division-with-new-buyout-deal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2198095
Dec 14, 2023 - Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.
0
Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes
https://www.zacks.com/stock/news/2197835/myriad-genetics-mygn-new-partnerships-aid-amid-fx-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2197835
Dec 14, 2023 - Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.
0
Here's Why You Should Retain Globus Medical (GMED) Stock Now
https://www.zacks.com/stock/news/2198889/here-s-why-you-should-retain-globus-medical-gmed-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2198889
Dec 15, 2023 - Investors are optimistic about Globus Medical (GMED) on growing demand for musculoskeletal devices and its strong solvency position.
0
Here's Why You Should Buy Neogen (NEOG) Stock Now
https://www.zacks.com/stock/news/2198536/here-s-why-you-should-buy-neogen-neog-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2198536
Dec 15, 2023 - Investors are optimistic about Neogen (NEOG), owing to product launches and the performance of segments.
0